交叉配血次侧不合的原因与输血疗效分析

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (989 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the causes and therapeutic effect of cross-matching blood by microcolumn agglutination. Methods The data of 498 patients with cross-matched blood were collected from Zhuxian Yi Memorial Hospital of Tianjin Medical University from January 2021 to October 2023, and the causes of main side compatibility and secondary side inconsistency of cross-matched blood were analyzed. Patients with positive direct antiglobulin test (DAT) were tested for DAT typing and chloroquine diphosphate release test to analyze the positive causes. Results A total of 1115 times of cross-matching were performed in 498 patients, and 446 times (40%) were detected. A total of 433 times (97.1%) were detected as DAT positive in the secondary mismatch, and 416 times (96.1%) were mainly monoclonal IgG types. IgG+C3d mixed type was 15 times, accounting for 3.5%, and simple C3d type was 2 times, accounting for 0.4%. After chloroquine diphosphate release test, the antibody screening test results of red blood cell release fluid of patients were negative. 60 patients with major side compatibility and secondary side incompatibility caused by DAT positive were transfused and transfused suspended red blood cells were selected. After transfusion, the values of hemoglobin (Hb), red blood cells (RBC) and hemocytocyte volume (HCT) were increased and in line with theoretical expectations. Total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) were all within the normal range, with no statistical difference (P>0.05). No hemolytic transfusion reaction occurred, and infusion was effective. Conclusions DAT positive is the main cause of main side compatibility and secondary side incompatibility in patients treated with blood transfusion. Transfusion of suspended red blood cells is safe and effective.

Key words： transfusion therapy secondary side incompatibility direct antihuman globulin test diffusion test transfusion efficacy

Received: 29 December 2023

ZTFLH:

R826.26

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YIN Chuangxin

Cite this article:

YIN Chuangxin. Analysis of causes of cross-matching secondary side incompatibility and transfusion efficacy[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(9): 781-783.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I9/781

[1]	汪德清.输血技术操作规程(输血科部分)[M].北京:人民卫生出版社,2016:92-119.
[2]	秦立红,蒋利星.微柱凝胶法配血试验2316例结果分析[J].国际检验医学杂志, 2012, 33 (4):500-502.
[3]	张丹,刘静,张静蕊,等.输血患者直接抗人球蛋白试验阳性结果病种分布情况分析[J].武警医学, 2023,34(12):1030-1033.
[4]	段秉政,王淑莲,连俊慧,等. 直接抗人球蛋白试验在患者输血疗效中的临床意义分析[J].临床输血与检验,2021,23(2):189-191.
[5]	兰炯采,陈静娴,武平英,等.推荐疑难配血三步分析法[J].中国输血杂志,2010,23(4):243-244.
[6]	林嘉,何屹,饶绍琴. 微柱凝集技术交叉配血主侧相合、次侧不合的处理流程研究[J]. 国际检验医学杂志,2015,36(5):581-585.
[7]	陈麟凤,庄健美,张金荣,等. 微柱凝胶法直接抗人球蛋白实验阳性强度的影响因素研究[J].重庆医科大学学报,2022,47(8):977-981.
[8]	蔡巧莲,魏寿忠,林桂花.微柱凝胶直接抗人球蛋白试验阳性分型与临床疾病相关性探讨[J].临床血液学杂志, 2018,224(2):25-27.
[9]	康晓珍,彭炜童,魏寿忠.直接抗人球蛋白试验阳性分型与输血疗效关系探讨[J].临床输血与检验,2022,24(3):338-342.
[10]	胡丽华.临床输血学检验技术[M].北京:人民卫生出版社,2015:152.
[11]	桂嵘.美国血库协会技术手册[M].19版.北京:人民卫生出版社,2020:263-265.
[12]	朱洁好,李伙桂,林楚霞,等.不规则抗体阴性受血者直接抗人球蛋白试验阳性的特征分析及类型鉴别[J].检验医学与临床,2021,18(11):1617-1619.
[13]	周朝霞,杨小红.74例直接抗人球蛋白试验阳性患者临床特征和RBC 输注效果分析[J].湖南师范大学学报(医学版),2020,17(3):60-63.
[14]	吴钢,段雨涵.Coombs试验在临床贫血及输血患者中的阳性分布率及其对临床输血的影响[J].中国实验血液学杂志,2018,26(1):223-227.
[15]	赵一贺,刘伟,赵媛.肾性贫血伴直接抗人球蛋白试验阳性患者输血疗效[J].继续医学教育, 2020, 34(9):66-68.
[16]	陈诚,姚祺敏,胡晓燕,等.输血后直接抗球蛋白试验结果阴性转阳性患者成分血输注效果分析[J].中国输血杂志,2021,34(8):854-857.
[17]	张慧莲,杨婷,于洋.680例交叉配血次侧凝集的结果分析[J]. 国际检验医学杂志, 2011, 32(9):1015.
[18]	Nathalang O, Sriwanitchrak P, Tubrod J,et al.Antibody elutionsin Thai patients with apositive direct antiglobulin test.BloodTransfus,2011,9(3):306-310.
[19]	王钰箐,雷航,龚淞颂,等.主次侧交叉配血不合患者输血疗效分析[J].中国输血杂志, 2021, 34(11):1218-1221.